Brivaracetam

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Brivaracetam

Examples of brand names: Briviact [EU/DE]

ATC code: N03AX23

Main use (for orientation): Epilepsy

Documented research summary

Five clinical cases with brivaracetam concentrations increased by 95–280% with CBD; not a controlled AUC study. CYP2C19 inhibition is a proposed explanation, not an established exclusive mechanism.

Uncertainties and limitations

The dominant hydrolysis pathway must not be replaced by an oversimplified CYP2C19 account.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – clinical signals

Finding ID: B0086

Type of result: Positive finding / indication

Observation: Concentrations +95 to +280%; two cases of mild adverse effects.

Mechanism: CYP2C19 inhibition suspected

Study type: Case series

Context studied: n=5; add-on CBD in epilepsy.

Clinical interpretation: Possible, individually relevant

Limitations and uncertainties: Mechanism/clinical threshold unresolved.

Original sources for this finding: Effects of cannabidiol on brivaracetam plasma levels [CL25]

References and access status

[CA_L_D0049] BRIVIACT (BRIVARACETAM) TABLET, FILM COATED BRIVIACT (BRIVARACETAM) SOLUTION BRIVIACT (BRIVARACETAM) INJECTION, SUSPENSION [UCB, INC.]

Original source / bibliographic reference

Authors: UCB, Inc.

Year: 2026

Source type: Current published human-use SPL / product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CL25] Effects of cannabidiol on brivaracetam plasma levels

Original source / bibliographic reference

Authors: Klotz KA; Hirsch M; Heers M; Schulze-Bonhage A; Jacobs J

Year: 2019

Source type: Case series

DOI: 10.1111/epi.16071

PMID: 31211851

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility